Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO5313534 add-on to donepezil in mild to moderate Alzheimer's disease
NCT00884507Phase 2Completed
- Sponsor
- Roche
- Start
- May 2009
- Primary completion
- Nov 2010
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 2, randomised, double-blind trial of facinicline in Alzheimer's disease (AD) (4 arms), sponsored by Roche. Primary endpoint: Alzheimer's Disease Assessment Scale-cognitive subscale at 24 weeks. Started May 2009; status: completed.
02
Drugs
facinicline
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00884507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00884507.